Navigation Links
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
Date:2/19/2008

ognostic and pharmacogenomic evaluations in their updated treatment guidelines.

Targeted Agents in Combination are Entering Clinical Trials

The validated association of aggressive disease and the overexpression of HEr2 in any type or stage of breast cancer have created a $4 billion global market for trastuzumab (Herceptin; Genentech) in 2007. Still, nearly 50% of HEr2-positive patients do not respond to trastuzumab, and survival benefits are transient, often lasting under a year. Furthermore, side effects remain a significant problem. Despite these limitations, trastuzumab is the standard of treatment for both early stage and advanced or metastatic disease and is undergoing clinical trials in combination with numerous approved or novel anticancer agents.

Hundreds of clinical trials are underway combining approved targeted therapeutics with every applicable cytotoxic(s) with the goal of achieving incremental benefits. The greater opportunity, however, may lie in combining targeted therapeutics that address different points in one pathway or interacting pathways involved in angiogenesis, metastasis, drug resistance, and tumor growth and survival. This approach has entered the clinic; recently initiated trials are testing combinations of approved targeted therapeutics with each other. The full impact of combining target agents, however, will not be measured until approved and novel agents are combined in hundreds of different combinations for the treatment of hundreds of specific cancer indications.

Future Oncology Series Details ErbB Pathway-targeted Therapeutics

To date, ErbB pathway abnormalities, which occur in a large number of malignancies, have been the most extensively targeted. Currently, there are 7 approved agents targeting this pathway and over 620 clinical trials are ongoing with these agents in various combinations, mostly with cytotoxic agents but also with each other and with selected novel agents under clinical develo
'/>"/>

SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
2. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
3. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
4. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/10/2014)... , July 11, 2014  Major advances ... of cancer are being highlighted in a three-day ... from 10-12 July, 2014.  Renowned national and ... share best practices and exchange knowledge on modern ... accurate and efficient. The Summit ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... May 22, 2012  Today ZocDoc introduces ... instant online access to appointments with Greater Denver,s ... . At launch, this free service provides patients ... with participating primary care doctors, obstetrician-gynecologists, dermatologists and ...
... BOONTON, N.J., May 22, 2012  Unigene Laboratories, ... design, delivery, manufacture and development of peptide-based therapeutics ... studies in rats and dogs for its lead ... a potent anorexigenic peptide selectively targeting the amylin ...
Cached Medicine Technology:Denver Patients Can Now Easily Find Doctors and Schedule Appointments Online 2Denver Patients Can Now Easily Find Doctors and Schedule Appointments Online 3Denver Patients Can Now Easily Find Doctors and Schedule Appointments Online 4Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 2Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 3Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 4Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 5
(Date:7/13/2014)... 14, 2014 Recently, iFitDress.com, one of ... released its beautiful collection of brown evening dresses ... are now available at discounted prices, up to 50% ... of high quality; they are carefully made according to ... occasion gowns, iFitDress.com also offers pretty accessories: wedding shoes, ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Roma vs. Real Madrid Tickets . For the fifth ... International Champions Cup will be held at American stadiums this ... world competing on American soil. The eight teams are split ... the group stage, the top two teams will compete to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Chromatography ... biological components from various types of biological samples ... separate the sample mixture into two phase, namely ... the mobile phase run over the stationary phase, ... the components that provide the separation of mixture. ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 A ... attention to the cancer risks associated with power morcellators ... tell their story to federal regulators, as they presented ... U.S. Food & Drug Administration (FDA) advisory panel meeting ... According to the Rochester Democrat and Chronicle, Dr. ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4
... Dynavax Technologies,Corporation (Nasdaq: DVAX ) today reported ... ended September 30, 2007. The results do not,include ... As of September 30, 2007, Dynavax reported ... Symphony Dynamo, Inc. (SDI),totaling $68.7 million. This compares ...
... global clinical,research organization, is pleased to announce that ... JCAHPO annual continuing education,program. Diana who designed an ... in ophthalmic practice for several years,prior to joining ... will take place in New Orleans, Louisiana from ...
... have for the first time found stem cells in ... such cells might someday be used to help repair ... , Reporting November 1, 2007 in the journal ... Irving Shapiro, Ph.D., at Jefferson Medical College of Thomas ...
... Video Component Enables Users to Upload Video Confessions/ ... on newfaceofresearch.com for Peer-to-Peer Viewing, PHILADELPHIA and ... Thomson Corporation (NYSE: TOC ; TSX: TOC) ... research and,business communities, today announced the launch of ...
... Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ) announced today ... Thursday, November 1, 2007, at 2:00 p.m.,Pacific, at the ... in San Diego, California. Spectrum,s presentation will be held ... The live webcast of Spectrum,s presentation will be available ...
... Health Inc.,(TSX: DAX) (Nasdaq: DRAX ) announces that ... he will retire as the President and Chief,Executive Officer ... Barkin joined the senior management of DRAXIS in 1992. ... guiding the Company through,a period of significant growth from ...
Cached Medicine News:Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 2Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 3Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 4Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 5Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 6Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 7Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 8Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 9Health News:Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting 2Health News:Jefferson researchers find stem cells in degenerating spinal discs, potential for repair 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Spectrum Pharmaceuticals to Present at the 2007 BIOCOM Investor Conference 2Health News:DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer 2Health News:DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer 3Health News:DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer 4
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
ACMI™ Double-J Closed Tip Ureteral Stents feature patented dual durometer thermosensitive Tecoflex® construction for physician ease of placement and patient comfort....
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... for interoperative placement to stent ... construction and continent urinary diversions. ... Intended for one-time use. CAUTION: ... must not remain indwelling more ...
Medicine Products: